Evidence map›Paper›PMID 39698290›Full record

ArticleACS pharmacology & translational science2024

Suppressing the Inflammatory Prostaglandin Signaling after Thrombotic Stroke Ameliorates Ischemic Brain Injury and Facilitates Poststroke Recovery.

Zhen Jin, Chenyao Jiang, Eun Bee Cho, Sina Bahraminejad, Juqian Han, Jiukuan Hao, Jiawang Liu, Ying Yu, Jianxiong Jiang

Abstract read
In one paragraph

Article in ACS pharmacology & translational science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zhen JinDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States.
Chenyao JiangDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States.
Eun Bee ChoDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States.
Sina BahraminejadDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States.
Juqian HanDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States.
Jiukuan HaoDepartment of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, Texas 77204, United States.ORCID https://orcid.org/0000-0003-2393-997X
Jiawang LiuDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States.
Ying YuDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States.
Jianxiong JiangDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States.ORCID https://orcid.org/0000-0003-3955-8928

Funding

Inflammatory regulation of neurotrophin signaling in epileptogenesisR01NS100947 · NINDS · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI Jianxiong Jiang · 2018 to 2026
$2.8M
Targeting the Hippo signaling at the Blood-brain barrier for therapy of ischemic strokeR01NS105787 · NINDS · UNIVERSITY OF HOUSTON · PI HAO, JIUKUAN · 2018 to 2023
$1.7M
EP2 Antagonists for Ischemic StrokeR61NS130199 · NINDS · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI JIANG, JIANXIONG, LIU, JIAWANG · 2023 to 2024
$752k
Inhibiting mPGES-1 as a countermeasure to mitigate organophosphate-induced neurotoxicityR21NS136070 · NINDS · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI JIANG, JIANXIONG · 2024 to 2025
$577k
NINDS NIH HHS R01 NS100947NINDS NIH HHS R01 NS105787NINDS NIH HHS R21 NS136070NINDS NIH HHS R61 NS130199
6 · The paper itself

Abstract

Acute cerebral ischemia is a leading cause of death and disability, particularly among old adults. The narrow therapeutic window and risk of hemorrhagic transformation largely limit patient eligibility for the current treatment. The neuroinflammatory signaling pathway involving the prostaglandin E2 (PGE

Identifiers

PMID39698290
PMCPMC11650728

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.